In a report released yesterday, Marc Goodman from Leerink Partners maintained a Buy rating on AC Immune SA (ACIU – Research Report), with a price target of $15.00. The company's shares closed last Monday at $5.15, close to its 52-week low of $4.68. According to TipRanks.com, Goodman is a 2-star analyst with an average return of 0.1% and a 42.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Satsuma Pharmaceuticals. AC Immune SA has an analyst consensus of Moderate Buy, with a price target consensus of $15.50.
https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-buy-rating-for-ac-immune-sa-aciu?utm_source=advfn.com&utm_medium=referral
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more AC Immune Charts.
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more AC Immune Charts.